MEDP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Medpace Holdings Inc (MEDP) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators are neutral, and there are no strong positive trading signals. Although the company has shown strong financial growth in revenue and net income, the mixed analyst ratings, reduced price targets, and lack of recent positive news or catalysts suggest waiting for a clearer entry point.
The MACD is negative and contracting, RSI is neutral at 40.806, and moving averages are converging. The stock is trading near its R1 resistance level of 454.028, with key support at 429.412. These indicators suggest a neutral trend with no clear buy signal.
Strong financial performance in Q4 2025, with revenue up 32.03% YoY and net income up 15.48% YoY. Analysts like Jefferies and Baird see potential for long-term growth due to biotech funding improvements and AI-driven efficiencies.
Mixed analyst ratings with several firms lowering price targets. Concerns over metabolic trial cancellations and AI disintermediation. Gross margin dropped by 12.13% YoY. No significant hedge fund or insider trading trends.
In Q4 2025, revenue increased by 32.03% YoY to $708.45M, net income grew by 15.48% YoY to $135.13M, and EPS rose by 26.98% YoY to 4.66. However, gross margin declined by 12.13% YoY to 27.97%.
Analyst sentiment is mixed. Jefferies upgraded the stock to Buy with a $560 target, citing favorable risk/reward and biotech funding improvements. However, TD Cowen and BMO Capital downgraded or lowered price targets due to concerns over cancellations and AI risks. Price targets range from $419 to $582.
